Roflumilast Foam 0.3% receives major FDA approval to treat seborrheic dermatitis

Roflumilast Foam 0.3% receives major FDA approval to treat seborrheic dermatitis

Arcutis BioTherapeutics today announced FDA approval of roflumilast foam 0.3% (Zoriway) for the treatment of seborrheic dermatitis in patients 9 years of age and older.1 Most notably, roflumilast foam 0.3% …

Read more

FDA seizes ‘thousands of units’ of counterfeit Ozempic as demand surges

FDA seizes 'thousands of units' of counterfeit Ozempic as demand surges

The U.S. Food and Drug Administration has warned patients of counterfeit Ozempic that is circulating through wholesalers, retail pharmacies and health care practitioners as Novo Nordisk’s drug remains in high …

Read more